11 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
15887966	58	Synthesis and structure-activity relationships of novel selective factor Xa inhibitors with a tetrahydroisoquinoline ring.	Central Pharmaceutical Research Institute
12904065	30	Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.	Lg Life Sciences
11170646	106	Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.	Dupont Pharmaceuticals
10794696	233	Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methylsulfonylisourea moieties at P1.	Universit£
9836616	92	Tetrahydro-isoquinoline-based factor Xa inhibitors.	Boehringer Mannheim
16137886	88	Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization.	Merck Research Laboratories
15501047	75	Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa.	Merck
11960487	30	Structure-based design of novel potent nonpeptide thrombin inhibitors.	Boehringer Ingelheim Pharma
11689072	49	Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.	Axys Pharmaceuticals
9822554	14	1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase.	Bristol-Myers Squibb Pharmaceutical Research Institute
9484495	74	Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa.	Collegeville